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Abstract We examined alterations in E/I-balance in schizophrenia (ScZ) through measurements
of resting-state gamma-band activity in participants meeting clinical high-risk (CHR) criteria (n = 88),
21 first episode (FEP) patients and 34 chronic ScZ-patients. Furthermore, MRS-data were obtained
in CHR-participants and matched controls. Magnetoencephalographic (MEG) resting-state activity
was examined at source level and MEG-data were correlated with neuropsychological scores and
clinical symptoms. CHR-participants were characterized by increased 64–90 Hz power. In contrast,
FEP- and ScZ-patients showed aberrant spectral power at both low- and high gamma-band
frequencies. MRS-data showed a shift in E/I-balance toward increased excitation in CHR-
participants, which correlated with increased occipital gamma-band power. Finally,
neuropsychological deficits and clinical symptoms in FEP and ScZ-patients were correlated with
reduced gamma band-activity, while elevated psychotic symptoms in the CHR group showed the
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opposite relationship. The current study suggests that resting-state gamma-band power and
altered Glx/GABA ratio indicate changes in E/I-balance parameters across illness stages in ScZ.
DOI: https://doi.org/10.7554/eLife.37799.001
Introduction
Emerging evidence suggests that efficient information transfer in neural networks depends crucially
upon the balance between excitation and inhibition (E/I-Balance) (Shu et al., 2003; Haider et al.,
2006). A shift in E/I-balance towards elevated excitability has been recently implicated in the patho-
physiology of schizophrenia (ScZ) (Driesen et al., 2013; Lisman, 2012; Murray et al., 2014;
Uhlhaas and Singer, 2012) and could provide a crucial intermediate phenotype that links basic cir-
cuit abnormalities with observations from non-invasive neuroimaging. However, it is currently unclear
when such abnormalities arise in the course of ScZ and their relationship to clinical and behavioural
features associated with the syndrome.
Among the circuit mechanisms that are involved in the maintenance of E/I-balance, parvalbumin-
expressing (PV+) g-Aminobutyric acid (GABA)ergic interneurons are of particular interest (Xue et al.,
2014) as inhibition of pyramidal cell activity regulates the output of cell-assemblies and leads to
rhythmic fluctuations in excitability or neural oscillations (Sohal et al., 2009; Kopell and LeMasson,
1994). Moreover, there is consistent evidence that a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid (AMPA)- and N-methyl-D-aspartate Receptor (NMDA-R)-mediated activation of PV+ interneur-
rons is essential for the generation of oscillatory activity (Carle´n et al., 2012; Fuchs et al., 2007),
especially at gamma-band (30–90 Hz) frequencies. In ScZ, converging evidence from genetics
(Pocklington et al., 2015), post-mortem data (Lewis et al., 2012) and brain imaging
(Kegeles et al., 2012) have supported the possibility that E/I-balance is disrupted which is consistent
with observations from electro/magnetoencephalographical (EEG/MEG)-data that task-related,
gamma-band oscillations are reduced (Uhlhaas and Singer, 2010).
One central prediction for a shift in E/I-balance in ScZ towards increased excitability-levels is an
increase in spontaneous gamma-band activity and a wealth of evidence from pre-clinical
(Yizhar et al., 2011; Kocsis, 2012; Pinault, 2008) as well as data in healthy controls following
NMDA-R hypofunctioning (Rivolta et al., 2015; Shaw et al., 2015) highlight that transient increases
in excitability are associated with enhanced occurrence of gamma-band power. For example,
NMDA-R antagonists have been show to increase spontaneous gamma-band activity in both human
(Rivolta et al., 2015) and pre-clinical research (Saunders et al., 2012).
Further support for the E/I-balance hypothesis comes from Magnetic Resonance Spectroscopy
(MRS) studies that have investigated alterations in Glutamate and GABA-concentrations across corti-
cal and subcortical areas. A consistent finding is an elevation of Glutamate-levels across illness-
stages in ScZ (Merritt et al., 2016) while the evidence for changes in GABA-levels is less consistent
(Egerton et al., 2017), supporting the view for a shift towards increased excitability of neural
circuits.
To provide further critical support for the E/I-balance hypothesis, we applied an advanced MEG
approach to examine resting-state MEG-recordings in participants meeting clinical high-risk criteria
(CHR), first-episode (FEP) and chronic ScZ-patients. Currently, there is only limited evidence available
from EEG/MEG-recordings in ScZ-patients (Rutter et al., 2009; Andreou et al., 2015;
Ramyead et al., 2015), which has tested comprehensively the pattern of spontaneous gamma-band
activity across illness-stages. MEG is characterized by an improved signal-to-noise ratio for measure-
ments of high-frequency oscillations compared to EEG (Muthukumaraswamy and Singh, 2013).
MEG is also ideally suited for source-reconstruction that allows the identification of the anatomical
lay-out of resting-state networks with high spatial resolution.
Accordingly, we focused on the following questions: (1) Are there differences in resting-state
gamma-band networks in ScZ and what is the direction of effects across different illness-stages? Pre-
vious data highlighted that the signatures of fMRI resting-state networks during early stage psycho-
sis, but not in chronic ScZ, resemble the acute effects of NMDA-R hypofunctioning (Anticevic et al.,
2015). In addition, there is evidence that glutamatergic neurotransmission is increased in younger
ScZ-patients (Marsman et al., 2013). Accordingly, we predicted that gamma-band activity in CHR
and possibly FEP-patients would be upregulated, while in chronic ScZ-patients the opposite pattern
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would occur. (2) Are gamma-band fluctuations related to clinical symptoms and cognitive deficits in
ScZ? Because of the role E/I-balance in shaping information transfer across large-scale networks
(Shu et al., 2003; Yizhar et al., 2011), we expected that alterations in gamma-band power would
closely correlate with neurocognitive deficits and clinical symptoms across clinical groups. (3) What is
the nature of alterations in resting-state gamma-band activity in ScZ? Changes could involve band-
limited as opposed to alterations across the entire gamma-band frequency with important implica-
tions for the interpretation of these phenomena. And (4) Are alterations in gamma-band power
in CHR-participants related to changes in GABA and Glutamate/Glutamine (Glx) concentrations?
Based on the relationship between E/I-balance and gamma-band power (Yizhar et al., 2011), we
predicted that CHR-participants would be characterized by an altered Glx/GABA-ratio that corre-
lates with increased high-frequency activity.
Results
Demographic and Clinical Characteristics
Table 1 summarizes demographic and clinical characteristics of participant groups. PANSS and
neurocognition data were available only for a subset of chronic ScZ and FEP-patients. The chronic
ScZ-group was significantly older than the control participants. There were also significantly more
females in the CHR than in the FEP and chronic ScZ-groups. FEP-patients were characterized by
higher ratings on the Excitation, Cognitive, Positive and Depression PANSS subscales and total
PANSS-scores than the chronic ScZ group. Neurocognitive data showed an overall increase in sever-
ity and range of cognitive deficits across the course of illness.
Resting-State Gamma-Band Power Across Illness-Stages in ScZ
Gamma-band resting-state power, separated in both low (30 – 46 Hz) and high (64 – 90 Hz) gamma-
band ranges, was estimated using the Dynamic Imaging of Coherence Sources (DICS) beamforming
approach (Gross et al., 2001). Main contrasts included (1) 88 CHR-participants against 48 controls
(CON1), (2) 21 FEP-patients, and (3) 34 chronic SCZ-patients, both against a second set of 37 con-
trols (CON2).
Low Gamma-Band (30–46 Hz) power
Significant differences from control data were observed for FEP and chronic ScZ groups, but not for
CHR-participants (Figure 1). FEP-patients showed significantly decreased prefrontal cortex
low gamma-band activity ( 2.15 < t(56)< 3.79, 0.002 < p < 0.006; see Table 2 for specific loca-
tions), while occipital cortex activity was increased (2.82 < t(56)<3.80, 0.002 < p < 0.006). In contrast,
chronic ScZ patients showed widespread decreased low gamma-band activity in frontal, temporal
and sensorimotor areas ( 2.35 < t(69)< 4.24, 0.002 < p < 0.006).
High Gamma-Band (64–90 Hz) power
Significant differences were found for all clinical groups in the 64–90 Hz range (Figure 1). A signifi-
cant increase in high gamma-band power was found in both midfrontal and posterior-occipital and
angular gyrus in CHR-participants (2.40 < t(134)<2.74, 0.002 < p < 0.006). In FEP and ScZ-patients,
changes in high gamma-band power were comparable to those seen at lower gamma-band frequen-
cies, with strong increases in posterior regions for the FEP-group (2.48 < t(56)<4.08,
0.002 < p < 0.006) and moderate decreases in frontal high gamma-band power in both FEP
( 2.42 < t(56)< 3.26, 0.002 < p < 0.006) and chronic SCZ-patients ( 2.40 < t(69)< 3.56,
0.002 < p < 0.006).
Resting-State Gamma-Band Power in CHR-Subgroups
We also assessed changes in gamma-band power in CHR-subgroups based on whether they met
CHR-criteria for Basic Symptoms as assessed by the Schizophrenia Proneness Instrument, Adult ver-
sion (SPI-A) (Schultze-Lutter et al., 2007), attenuated psychotic symptoms defined by
the Comprehensive Assessment of At Risk Mental States (CAARMS) interview (Yung et al., 2005) or
on both measures. Previous data (Schultze-Lutter et al., 2014) indicated that different CHR-groups
are associated with differential risks for psychosis, with CHR-participants meeting both CAARMS/
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Table 1. Demographical and clinical data.
CHR
(n = 88)
CON1
(n = 48)
FEP
(n = 21)
SCZ
(n = 34)
CON2
(n = 37) GROUP effect* Pairwise comparisons* H/p -values
Age (mean/SEM)
22.0/0.5 22.7/0.5 27.0/1.5 37.1/2.0 28.6/1.2 H(4)=80.8
p<0.0001
CHR vs. FEP
CHR vs. SCZ
 54.6/0.006
 104.5/0.000
Sex (mean/SEM)
female/male 67/21 33/15 5/16 12/22 13/24 H(4)=38.9
p<0.0001
FEP vs. CHR
CON2 vs.CON1
59.6/0.000
38.2/0.020
Education (mean/SEM)
Years 15.5/0.5 16.6/0.4 14.1/0.7 14.2/0.6 16.6/0.6 H(4)=16.7
p=0.002
CON1 vs. SCZ 41.8/0.027
BACS†
(mean/SEM)
CHR
(n = 88)
CON1
(n = 48)
FEP
(n = 18)
SCZ
(n = 28)
CON2
(n = 37)
GROUP
effect
Pairwise
comparisons H/p -values
Verbal Memory  0.36/0.17 0.23/0.17  0.41/0.38  0.93/0.24 0.79/0.14 H(4)=26.5
p<0.0001
SCZ vs. CON2  76.1/0.000
Digit Sequencing  0.39/0.12  0.07/0.11 0.26/0.36  1.07/0.20 0.62/0.17 H(4)=35.5
p<0.0001
SCZ vs. FEP
SCZ vs. CHR
SCZ vs. CON2
66.9/0.003
38.6/0.036
 90.1/0.000
Token Motor Task  0.64/0.15 0.28/0.16 0.60/0.27 0.47/0.21 1.39/0.15 H(4)=56.9
p<0.0001
SCZ vs. CHR
CHR vs. CON1
CHR vs. FEP
SCZ vs. CON2
46.9/0.004
 37.8/0.005
 54.5/0.006
 45.3/0.050
Verbal Fluency 0.15/0.12 0.38/0.19  0.85/0.49  0.90/0.20 0.64/0.21 H(4)=27.1
p<0.0001
SCZ vs. CHR
FEP vs. CON2
SCZ vs. CON2
52.0/0.001
 51.7/0.000
 73.3/0.000
Symbol Coding  0.04/0.14 0.62/0.16  0.96/0.27  1.19/0.23  0.26/0.15 H(4)=46.6
p<0.0001
SCZ vs. CHR
FEP vs. CHR
SCZ vs. CON2
CHR vs. CON1
57.0/0.000
44.5/0.049
 48.0/0.030
 32.4/0.031
Tower of London 0.18/0.12 0.28/0.10 0.51/0.24  0.19/0.21 0.85/0.13 H(4)=15.0
p<0.0001
SCZ vs. CON2  76.1/0.000
COMPOSITE
score
 0.31/0.14 0.46/0.10  0.22/0.35  1.03/0.21 1.11/0.11 H(4)=61.0
p<0.0001
SCZ vs. CON2
FEP vs. CON2
CHR vs. CON1
 111.3/0.000
 72.1/0.001
 38.5/0.004
PANSS (mean/SEM)
FEP
(n = 16)
SCZ
(n = 30)
GROUP
effect
Negative 18.0/1.3 16.6/1.1 not sign diff
Excitation 9.4/0.8 7.2/0.7 H(1)=6.1, p=0.013
Cognitive 12.3/1.1 10.5/0.7 not sign diff
Positive 12.5/0.7 9.8/0.7 H(1)=5.1, p=0.024
Depression 14.8/1.1 12.2/0.6 H(1)=3.9, p=0.047
TOTAL 66.9/3.2 56.3/3.0 H(1)=5.4, p=0.020
CAARMS
(mean/SEM)
*frequency
CHR
(n = 88)
SPI-A
(n = 25)
CAARMS
(n = 29)
BOTH‡
(n = 34)
GROUP
effect
Pairwise
comparisons H/p -values
Unusual Thought
Content
5.2/0.8 3.6/1.4 3.9/1.1 7.6/1.3 H(2)=6.8
p=0.033
not sign diff
Non-Bizarre
Ideas
9.9/0.8 5.6/1.1 9.7/1.4 13.3/1.3 H(2)=14.3
p=0.001
SPI-A vs. SPI-A+CAARMS  25.2/0.000
Perceptual
Abnormalities
8.1/0.7 3.9/0.7 9.4/1.3 10.2/1.1 H(2)=15.7
p<0.0001
SPI-A vs. SPI-A+CAARMS
SPI-A vs. SPI-A+CAARMS
 21.5/0.006
 25.2/0.000
Disorganized
Speech
4.3/0.6 3.8/0.9 2.1/0.8 6.5/0.9 H(2)=11.9
p=0.003
CAARMS vs. SPI-A+CAARMS  20.8/0.002
TOTAL 27.6/1.8 16.8/2.9 25.0/2.4 37.6/2.8 H(2)=22.2
p<0.0001
SPI-A vs. SPI-A+CAARMS
CAARMS vs. SPI-A+CAARMS
 31.4/0.000
 17.4/0.021
Table 1 continued on next page
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SPI-A criteria having the highest risk for the development of psychosis followed by CAARMs and
SPI-A only groups.
The combined SPI-A/CAARMS group was characterized by increased frontal and posterior cortex
64–90 Hz power (Figure 2: 2.16 < t(80)<3.43, 0.002 < p < 0.006) which was not present in the SPI-A
only group. CHR-participants who only met CAARMS criteria showed moderately increased middle
frontal and occipital cortex high gamma-band power (Figure 2: t(75) = 2.67, p=0.006).
Interestingly, the increase in upregulated occipital cortex high gamma-band activity in the com-
bined SPI-A/CAARMS groups showed an overlap with the pattern observed in the FEP-group (Fig-
ure 3), but was not present in chronic ScZ-patients, whereas the down-regulated gamma-band
power in frontal, temporal and sensorimotor regions was only seen in patients with ScZ but not in
CHR-participants.
Broadband vs. Band-Limited Gamma-Band Power Group Differences
We examined further the alterations in gamma-band activity to determine whether these changes
encompassed specific frequency bins vs. a broad-band change across the entire gamma (30 – 90 Hz)
frequency range. To this end, we examined AAL-atlas data in the gamma-band range extracted
from central nodes within each significant AAL region of reported group differences (Table 2), sepa-
rately for each 5 Hz bin. Statistical analyses of these data confirmed that all reported group-specific
gamma-band power effects were broadband in nature (see Figure 2—figure supplement 1).
Correlations with Clinical Symptoms and Demographic Data
We also systematically explored relationships between gamma-band power and demographic data
(age, sex), psychopathology (total CAARMS, total PANNS scores) and neurocognitive (composite
BACS scores) variables, given recently reported strong covariation of both symptoms, age and sex
on neuroimaging phenotypes and thus the need to incorporate them in evaluating patient data
(Moser et al., 2018). Our goal was to determine how each factor influenced findings across the
regions of significant gamma-band changes between CHR-, FEP and chronic ScZ-patients vs. con-
trols. This approach was expected to most optimally highlight regional differences in sensitivity to
each individual covariate, as the data was permuted across the covariate data rather than across
gamma-band power data from all participants.
The results for low- and high gamma-band activity are summarized in Figure 4. Both total
CAARMS and composite BACS scores correlated with gamma-band power, especially in the 64 – 90
Hz frequency range, in the CHR-group, suggesting that increases in gamma-band activity were
related to neurocognitive deficits and elevated psychotic symptoms. Similar relationships were
observed for the FEP-group for posterior areas, while frontal and central regions showed an
Global Functioning
(GAF:
mean/SEM)
CHR
(n = 88)
CON1
(n = 48) GROUP effect
59.8/1.2 87.4/1.0 H(1)=81.0, p<0.0001
MEDICATION
CHR
(n = 88)
CON1
(n = 48)
None 39 46
Anti-psychotic 1 0
Mood-stabilizer 1 0
Anti-depressant 20 0
Anti-convulsant 0 0
Other 11 0
Multiple 16 2
*Kruskal-Wallis independent-sample test. Alpha-level 0.05, two-sided with p-values adjusted for ties.
†Kruskal-Wallis independent-sample test performed on z-standardized data (Keefe et al., 2008). Alpha-level 0.05, two-sided, p-values adjusted for ties.
DOI: https://doi.org/10.7554/eLife.37799.002
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opposite relationship. In the chronic ScZ-group, BACS and PANSS-scores were mostly correlated
with a reduction of gamma-band power, especially in the lower gamma-band range.
Across groups, modest correlations were observed between age and sex. In the chronic ScZ-
group, widespread correlations at both low and high gamma-band ranges were observed with age.
The contribution of age to the main effects found in the chronic ScZ group was further investi-
gated by repeating the main analyses on a sub-sample of age-matched ScZ (n = 25; mean age 32.2)
and control participants (n = 25; mean age 31.6). The results revealed a similar pattern to those
reported above (see Figure 4—figure supplement 1).
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Figure 1. Whole-Brain Gamma-Band Power Group Differences Across Illness-Stages. (A) Low gamma (30–46 Hz) source-power differences for the three
main group contrasts: CHR vs.CON1 (left panel), FEP vs.CON2 (middle panel), ScZ vs.CON2 (right panel). Sources were estimated using a DICS
beamformer method. Slice- and surface plot representations are shown with t-values corresponding to significant voxels (non-parametric, Monte-Carlo
permutation based independent t-tests, FDR corrected at p<0.05, two-sided). Red colors (positive t-values) indicate an increase in gamma-band power
compared to controls, whereas blue colors (negative t-values) reflect decreased gamma-band power in the clinical groups. (B) As panel A, but for high
gamma (64 – 90 Hz) band activity.
DOI: https://doi.org/10.7554/eLife.37799.003
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MRS-Data
MEGAPRESS MR-Spectroscopy was used to measure GABA and Glutamate/Glutamine (Glx) concen-
trations in the CHR and CON1 participants, focused on a 2  2  2 cm voxel covering the right mid-
dle occipital gyrus (Figure 5). Data from 69 CHR participants and 35 controls were of sufficiently
high quality to use for further analyses. Results from one-way repeated-measures ANOVAs showed
that, compared to controls, the CHR-group showed significantly higher excitatory Glx concentrations
in right middle occipital gyrus (F(1,102) = 4.3, p=0.041, Welch-t = 5.9, p=0.017, LSD corrected), in
the absence of changes in GABA concentrations (Figure 5). The imbalance in concentrations
between excitatory Glx and inhibitory GABA concentrations in CHR-participants was evident also in
a significantly increased Glx/GABA ratio (F(1,102) = 4.5, p=0.037, Welch-t(102)=5.8, p=0.018, LSD
corrected).
Correlations between high gamma-band (64– 90 Hz) power and MRS estimates of Glx, GABA and
Glx/GABA ratio scores were investigated using non-parametric, Monte-Carlo based (1000 permuta-
tions, independent sample regression coefficient T-statistics, alpha = 0.05, two-sided, FDR cor-
rected) on data covering striate (calcarine fissure, cuneus, lingual gyrus) and extrastriate (superior,
middle and inferior occipital gyrus) visual areas, including all available data (n = 104; 69 UHR plus 35
CON). These analyses showed that changes in Glx and Glx/GABA ratio correlated significantly
(p<0.05, uncorrected) with increased right and left calcarine and right middle occipital gyrus
Table 2. Overview of AAL regions of significantly modulated resting-state low and high gamma-band power.
Group contrast Labels of significant AAL regions*
t-values
(range)
p-values
(range)
Low GAMMA (30–46 Hz)
FEP vs CON2 left Calcarine Fissure,
left Inferior Occipital Gyrus
2.82 to 3.80 0.002–0.006
right and left Superior Medial Frontal Gyrus,
right Middle Frontal Gyrus
 2.15 to  3.79 0.002–0.006
SCZ vs CON2 right and left Superior Medial Frontal Gyrus,
right Middle Frontal Gyrus,
left Inferior Parietal Lobule,
left Superior Orbital Frontal Gyrus,
left Superior Temporal Gyrus,
left PostCentral Gyrus,
right PreCentral Gyrus
 2.35 to  4.24 0.002–0.006
High GAMMA (64–90 Hz)
CHR vs CON1 left Middle Occipital Gyrus,
right and left Middle Frontal Gyrus,
left Angular Gyrus,
left Inferior Parietal Lobule
2.40 to 2.74 0.002–0.006
SPI-A only vs CON1 No significant voxels    
CAARMS only vs CON1 left Middle Frontal Gyrus,
left Middle Occipital Gyrus
2.67 0.006
CAARMS + SPI A vs CON1 right and left Middle Occipital Gyrus,
right and left Middle Frontal Gyrus.
left Angular Gyrus,
right Inferior Parietal Lobule, left Superior Medial Frontal Gyrus
2.16 to 3.43 0.002–0.006
FEP vs CON2 right and left Calcarine Fissure, right and left Inferior Occipital Gyrus,
right and left Middle Occipital Gyrus,
right and left PreCuneus,
left Inferior Frontal Gyrus,
left Angular Gyrus
2.48 to 4.08 0.002–0.006
right Middle Frontal Gyrus  2.42 to  3.26 0.002–0.006
SCZ vs CON2 right and left Superior Medial Frontal Gyrus,
left Superior Orbital Frontal Gyrus, left Middle Orbital Frontal Gyrus, left PostCentral
Gyrus
 2.40 to  3.56 0.002–0.006
*Non-parametric Monte-Carlo permutation based independent-sample tests, alpha-level 0.05, two-sided, FDR corrected voxels.
DOI: https://doi.org/10.7554/eLife.37799.004
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high gamma-band power (Figure 5). In addition, increased high gamma-band power correlated sig-
nificantly with decreased calcarine fissure GABA concentrations as well as with increased Glx/GABA
ratio (p<0.05, FDR corrected).
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Figure 2. Whole-Brain Gamma-Band Power for CHR-Groups. (A) Low gamma-band (30–46 Hz) source-power differences for the three CHR-group
contrasts: SPI-A vs.CON1 (left panel), CAARMS vs.CON1 (middle panel), CAARMS + SPI-A vs.CON1 (right panel). Sources were estimated using a DICS
beamformer method. Slice- and surface plot representations are shown with t-values corresponding to significant voxels (non-parametric, Monte-Carlo
permutation based independent t-tests, FDR corrected at p<0.05, two-sided). Red colors (positive t-values) indicate an increase in gamma-band power
compared to controls, whereas blue colors (negative t-values) reflect decreased gamma-band power in the clinical groups. (B) As panel A, but for high
gamma (64 – 90 Hz) band activity.
DOI: https://doi.org/10.7554/eLife.37799.005
The following figure supplement is available for figure 2:
Figure supplement 1. Broadband nature of gamma band effects.
DOI: https://doi.org/10.7554/eLife.37799.006
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Discussion
Emerging evidence suggest that circuit dysfunctions underlying the symptoms and cognitive deficits
in ScZ may be caused by an alteration in E/I-balance parameters (Uhlhaas and Singer, 2012;
Anticevic et al., 2012). However, direct physiological evidence for this hypothesis from non-invasive
electrophysiological and neuroimaging data is so far scarce. The current study addressed this ques-
tion through the investigation of resting-state gamma-band activity and MRS Glx/GABA levels, two
important signatures of E/I-balance (Yizhar et al., 2011; Rowland et al., 2005), across illness stages
of ScZ in MEG-data and their relationship to clinical and neuropsychological variables. Recent evi-
dence suggests that early stage psychosis may be characterized by distinct neural signatures com-
pared to chronic ScZ (Anticevic et al., 2015), involving a gradual shift of E/I-balance that implicates
elevated glutamatergic neurotransmission at illness-onset.
Consistent with this hypothesis, we observed distinct patterns of resting-state gamma-band
power in CHR-, FEP- and chronic ScZ-groups. Specifically, CHR-participants were characterized by
increased gamma-band power compared to both FEP and chronic ScZ in a network including frontal
and right temporal structures. FEP-patients showed largely reduced 30–90 Hz power over frontal,
central and temporal areas but also showed additional increases in visual areas not observed in the
chronic ScZ-group.
Importantly, the changes observed in gamma-band power across illness stages covered the entire
30–90 Hz frequency range, except for the CHR group where the increases in spectral power selec-
tively involved the 64–90 Hz frequency band, suggesting that high gamma-band activity may
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Figure 3. Illness Severity and Aberrant Gamma Activity. Surface-projected statistical group differences in low gamma (30–46 Hz; left column) and high
gamma-band (64–90 Hz; right column) for all main and the three CHR-subgroups contrasts. Values represent t-values corresponding to significant
voxels (p<0.05; uncorrected, masked at critical t-values of non-parametric, Monte-Carlo permutation independent t-tests).
DOI: https://doi.org/10.7554/eLife.37799.007
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constitute a marker for psychosis-risk. Overall, the pattern of spectral changes is distinct from activity
associated with an oscillatory process observed during task-contexts (Hoogenboom et al., 2006;
Fries et al., 2008), whereby a circumscribed modulation within a particular frequency is considered
to be the hallmark of an oscillation.
The broad-band modulation observed in our data is compatible with the effects of impaired
NMDA-R on PV+ cells. Carle´n et al. (2012) showed that reduced NMDA-R neurotransmission on
PV+ interneurons is associated with increased broad-band gamma-band power at rest while the abil-
ity to generate gamma-band oscillations after optogenetic drive of PV-interneurons was reduced.
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Figure 4. Clinical and Demographical Variables and Gamma-band Effects. Overview of the influence of AGE, SEX, total CAARMS, total PANSS, and
composite BACS scores on low g and high gamma-band power GROUP differences. As with the main effects of GROUP, non-parametric, Monte-Carlo
permutation-based independent t-test were used to test for GROUP differences, but data was permutated over the control variable data rather than
the actual gamma-band source power data. The resulting remaining significant activity then represents the interaction between the main group effect
and the variation in the control variable. Surface-projected interaction-effects are shown between control groups and CHR group: (top panel), FEP
group (mid panel) and chronic SciZ group (lower panel).
DOI: https://doi.org/10.7554/eLife.37799.008
The following figure supplement is available for figure 4:
Figure supplement 1. Influence of Control Variable AGE on main GROUP effect and interaction effect.
DOI: https://doi.org/10.7554/eLife.37799.009
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These data thus also replicate the large body of evidence for impaired generation of task-related,
band-limited gamma-band oscillations in ScZ (Uhlhaas and Singer, 2010; Thune´ et al., 2016),
highlighting the crucial importance of impaired E/I-balance for the explanation for alterations in
both resting-state as well as task-related gamma-band activity in ScZ.
Elevated excitation due to NMDA-R hypofunctioning has been implicated as a possible mecha-
nism for the emergence of psychosis (Schobel et al., 2013) that could transiently lead to elevated
high-frequency activity. This hypothesis is crucially supported by the MRS-data of Glx/GABA concen-
trations. Specifically, we observed that Glx-levels were elevated while GABA-concentrations were
intact in CHR-participants, highlighting that psychosis-risk is intimately related to elevated glutama-
tergic neurotransmission. This hypothesis is consistent with previous MRS-data of elevated Glx-levels
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in CHR-participants (de la Fuente-Sandoval et al., 2011; Tandon et al., 2013) and findings in FEP
(Kahn and Sommer, 2015).
The current findings critically extend these data by demonstrating that increased Glx-levels
extend into visual cortex, which is consistent with evidence that alterations in visual perception may
be indicative for transition to ScZ in CHR-participants (Klosterko¨tter et al., 2001). Moreover, our
findings provide the first link between changes in E/I-balance parameters and fluctuations in gamma
band power as increased Glx and Glx/GABA ratio correlated significantly with elevated 30-90 Hz
activity.
The functional significance of the changes in resting-state gamma-band activity is underlined by
the close relations with both neurocognitive and clinical parameters. During normal brain function-
ing, E/I-balance is fundamental for shaping information transmission of large-scale networks
(Yizhar et al., 2011; Saunders et al., 2012). Consistent with this hypothesis, we observed that the
degree of reductions in 30–90 Hz gamma-band power in both FEP and chronic ScZ-patients corre-
lated with impairments in cognition and symptoms of emerging psychosis. In the CHR-group,
impaired neurocognition correlated with elevated 64–90 Hz power while the presence of attenuated
psychotic symptoms showed the opposite relationship. In contrast, deficits in neurocognition in FEP-
and chronic ScZ-patients showed a robust correlation with reductions in gamma-band power,
highlighting that disruptions in E/I-balance across illness stages in ScZ can potentially account for
relations with cognitive impairments.
Robust relationships were observed between reductions in gamma-band power with age, in par-
ticular in the chronic ScZ-group. Previous MRI-data has highlighted that reduction in GM could
reflect an accelerated aging process in ScZ, possibly related to outcome and medication
(Schnack et al., 2016). Accordingly, one scenario is that the reductions in spectral power in chronic
ScZ-patients reflect progressive pathophysiological processes that lead to circuit dysfunctions as
reflected by an impaired generation of high-frequency activity and pronounced cognitive deficits.
Moreover, it is conceivable that anti-psychotic medication may also contribute to the observed
reductions in gamma-band power across the illness course as loss of GM has been associated with
antipsychotic exposure (Ho et al., 2011) and pre-clinical evidence suggests that antipsychotic medi-
cations can reduce gamma-band oscillations (Schulz et al., 2012).
The current data have implications for the interpretation of gamma-band fluctuations and the
pathophysiology of ScZ. Spontaneous changes in gamma-band power are representing a distinct
aspect of electrophysiological changes typically observed during task-related scenarios that could
provide important insights into circuit abnormalities. Thus, increased spiking activity at high frequen-
cies may interfere with the generation of task-related oscillations as has been proposed previously
(Hirano et al., 2015). However, we would like to note that contrary to empirical findings, this sce-
nario likely applies primarily to early stage psychosis as chronic ScZ-patients were characterized by
reduced gamma-band power.
The study has several limitations. Notably, the current conclusions are based on cross-sectional
findings. Accordingly, follow-up data need to determine whether increased resting-state gamma-
band power is also predictive for clinical outcomes in CHR-populations. In addition, there were dif-
ferences in age- and sex-composition across clinical samples. We would like to note that the rescal-
ing procedure employed and matched control participants for the CHR- and FEP-groups highlight
that differences in gamma-band power represent the effects of different stages of psychosis. Sec-
ondly, it is currently unclear whether the trajectory of changes in spectral power could be influenced
by anti-psychotic medication. However, we would like to emphasize that the large majority of CHR-
participants and FEP-patients were currently not being treated with antipsychotic medication.
Accordingly, it is unlikely that medication effects drove the differences at illness-onset in gamma-
power.
Finally, the current study did not examine dynamic aspects of resting-state activity. There is evi-
dence to suggest resting-state networks are not stationary. Accordingly, future studies could exam-
ine alterations in micro-states and related phenomena, such as approaches employing a Hidden
Markov Model (HMM), to provide further insights into alterations of resting-state activity in ScZ
(Rieger et al., 2016; Vidaurre et al., 2018).
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Conclusion
The current study provides novel evidence for alterations in E/I-balance parameters in the patho-
physiology of ScZ through a combination of MRS and advanced MEG. Specifically, our findings high-
light that increased high gamma-band power and a shift toward increased excitation over inhibition
are a hallmark of early stage psychosis and are potentially consistent with the NMDA-R hypofunc-
tioning model of psychosis. These findings have implications for current pathophysiological theories
emphasizing a shift towards increased excitation in the early stage of ScZ, with possible implications
for the development of treatments and biomarkers for early detection and diagnosis. Accordingly,
future studies should investigate the possibility of utilizing resting-state gamma-band power as spec-
tral fingerprints (Siegel et al., 2012) to predict onset of psychosis as well as treatment outcomes.
Materials and methods
Participants
The following groups of participants were recruited: (1) A sample of participants meeting CHR-crite-
ria (n = 88) from the ongoing Youth Mental Health Risk and Resilience (YouR) Study (Uhlhaas et al.,
2017) and 48 matched controls (CON1) (2) A group of 21 antipsychotic-naı¨ve ScZ patients who were
experiencing their first episode of psychosis (FEP), 34 patients with chronic ScZ who were on stable
antipsychotic-medication treatment and 37 matched controls (CON2). A total of n = 22 participants’
data were excluded due to excessive muscle and movement artefacts (10 CHR, 3 FEP, 4 chronic ScZ
and 5 controls).
CHR-participants were recruited from NHS-services and the general population. CHR-criteria
were established through the Comprehensive Assessment of At Risk Mental States (CAARMS) Inter-
view (Yung et al., 2005) for the assessment of attenuated psychotic symptoms and the Cognitive
Disturbances and Cognitive-Perceptive Basic Symptoms (COGDIS/COPER) items of the Schizophre-
nia Proneness Instrument, Adult version (SPI-A) (Schultze-Lutter et al., 2007). Basic symptoms
describe a range of self-experienced cognitive and perceptual abnormalities that are predictive for
the development of ScZ (Klosterko¨tter et al., 2001).
CHR-participants were excluded for current or past diagnosis with Axis I psychotic disorders,
including affective psychoses, as determined by the Structured Clinical Interview for the Diagnostic
and Statistical Manual of Mental Disorders-IV (SCID). Other co-morbid Axis I diagnoses, such as
mood or anxiety disorders, were not exclusionary and all participants were between 16 – 35 years of
age (for more details, see Uhlhaas et al. (2017) and Table 1).
FEP ScZ-patients were recruited from the Department of Psychiatry and Psychotherapy, University
of Cologne, and chronic ScZ patients from the Department of Psychiatry, Psychosomatics and Psy-
chotherapy, Goethe University Frankfurt. Current psychopathology was examined with the Positive
and Negative Symptom Scale (PANSS) (Kay et al., 1987). Control participants were screened for
psychopathology with the SCID and/or the MINI-SCID interview (Sheehan et al., 1998). Neurocogni-
tion for all participant groups was assessed with the Brief Assessment of Cognition in Schizophrenia
(BACS) (Keefe et al., 2004).
The study was approved by the ethical committees of the Goethe University Frankfurt and the
NHS Research Ethical Committee Glasgow and Greater Clyde. All participants provided written
informed consent.
Neuroimaging
CHR- and a matched control-group (CON1) were assessed at the Centre for Cognitive Neuroscience
(CCNi), University of Glasgow. Five minutes, eyes-open resting-state was acquired using a 248-chan-
nel 4D-BTI magnetometer system (MAGNES 3600 WH, 4D-Neuroimaging, San Diego), recording at
a sampling frequency of 1017.25 Hz, filtered online between DC and 400 Hz. FEP- and chronic ScZ-
patients, and matched controls (CON2) were recorded at the Brain Imaging Centre (BIC), Goethe-
University, Frankfurt, Germany. MEG resting-state activity was recorded with a 275-channel CTF sys-
tem (Omega 2005, VSM MedTech Ltd., BC, Canada), recording at a sampling frequency of 600 Hz
with a synthetic third order axial gradiometer configuration. Online filtering was applied using a 4th
order Butterworth filter with 0.5 Hz high-pass and 150 Hz low-pass.
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3D MPRAGE sequences were used to collect the T1-weighted data (Allegra 3Tesla scanner, BIC-
Frankfurt: 160 slices, voxel size 1 mm3, FOV = 256 mm3, TR = 2300 ms, TE = 3.93 ms; Trio 3Tesla
scanner, CCNi-Glasgow: 192 slices, voxel size 1 mm3, FOV = 256256  176 mm3, TR = 2250 ms,
TE = 2.6 ms, FA = 9˚).
MEG Data Analysis
MEG data were analysed with MATLAB using the open-source Fieldtrip Toolbox. Faulty MEG sen-
sors (CTF data: mean (± SEM)=1 ± 0.2; 4D-BTI data: 18 ± 0.1, visually identified) expressing large sig-
nal variance or flat signals were removed from the data. For all 228 participants, the first 4 min of
MEG resting-state data, available for all groups, were used in the analyses, downsampled to 400 Hz.
These data were epoched into 240 non-overlapping trials of one-second duration, after first attenu-
ating the (residual) 50 Hz line noise signal with a discrete 50 Hz Fourier transform filter. The Glasgow
magnetometer data was additionally denoised offline relative to available MEG reference channel
signals. Artifact-free data were created by removing trials with excessive transient muscle activity,
slow drift or SQUID jumps using visual inspection, followed by ICA-based removal of eye-blink, eye-
movement and ECG artifacts. This resulted in 215 ± 2.6 trials for FEP-patients, 215 ± 2.0 trials for
chronic ScZ-patients, 218 ± 1.6 trials for CON2-, 220 ± 0.7 trials for CHR-, and 219 ± 1.1 trials for
CON1-groups.
Whole-brain source gamma-band power (FFT data between 30 – 90 Hz, hanning tapered) was
estimated using the Dynamic Imaging of Coherence Sources (DICS) beamforming approach
(Gross et al., 2001) on a 5 mm grid based on the MNI template brain. We differentiated between a
low (30 – 46 Hz) and high (64 – 90 Hz) gamma-band to avoid contamination of line-noise artifacts
around 50/60 Hz, and because of evidence that low and high-frequency bands have distinct generat-
ing mechanisms and functional roles (Veit et al., 2017; Oke et al., 2010; van der Meer and Redish,
2009).
Prior to source estimation as well as FFT computations, data were rescaled separately per trial
and channel to values between 0 and 1 (formula: X(t) – minamp/(maxamp-minamp), with X(t) repre-
senting raw amplitude at time t, and minamp/maxamp estimated across time). Our tests showed
that this linear rescaling procedure was robust against changes in topographic distribution of activity
(including source estimations) and spectral power shifts. The procedure was applied to correct for
(1) higher variance in overall brain activity levels in the FEP, ScZ patients and, to some extend also in
the CHR participants, compared to healthy controls, and (2) MEG-system differences in global activ-
ity levels and sensor types (CTF gradiometers vs. 4D-BTI magnetometers).
1H-MRS Data Acquisition
MRS data were acquired on a Siemens Trio 3Tesla scanner and only for the CHR-group and their
respective controls. The 3D MPRAGE anatomical images were first resliced into axial and coronal
views to allow more precise and consistent placement of a single 2  2  2 cm3 voxel, using all three
planar views, in the right middle occipital gyrus, about 1 cm to the right of the calcarine fissure and
aligned within a few millimeters from the edge of voxel (see Figure 5). FASTMAP (Gruetter and
Tka´c, 2000) shimming of the voxel was used to improve local-field homogeneity in the area of inter-
est. Three scans were acquired, including a full spectrum acquisition, a GABA-edited MEGA-PRESS
(WIP: VB-17A) scan (128 trials), and an unsuppressed water scan (64 trials). For the current study, the
last two scans were used to quantify GABA and co-edited combined Glutamate/Glutamine (Glx) con-
centrations. MEGA-PRESS scanning parameters included: TR/TE = 1500/68 ms, 1.9 ppm ON- and
1.5 ppm OFF-resonance editing pulse frequencies (i.e., symmetric editing to suppress macromole-
cule contribution), 44 Hz editing Gaussian pulse bandwidth, delta frequency of  1.7 ppm relative to
water, 50 Hz water suppression, 90˚ flip angle, acquisition bandwidth of 1200 Hz, duration 426 ms,
number of points 512.
Post-Processing of MR Spectroscopy Data
Metabolite quantification of the MEGA-PRESS difference spectra was performed using the Matlab
Toolbox Gannet 2.1 (Edden et al., 2014). Gannet-guided post-processing steps included combina-
tion of phased array coil data, time-domain frequency-and-phase correction using spectral correc-
tion, exponential line broadening, Fast Fourier Transformation (FFT), averaging, frequency and
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phase correction based upon fitting of the Choline and Creatine (Cr) signals, pairwise rejection of
data for which fitting parameters were greater than three standard deviations from the mean, and
finally subtraction to generate the edited difference spectrum.
For quantification of our metabolites of interest - GABA at 3 ppm and the co-edited Glx at 3.75
ppm - the area under the peak of GABA, Cr, and unsuppressed water (3 ppm), as well as Glx (at
3.75 ppm) were estimated, using a nonlinear fit procedure with a single Gaussian superimposed on
a linear baseline. To account for individual differences in amounts of voxel gray matter (GM), white
matter (WM) and cerebrospinal fluid (CSF) fractions, GABA concentrations were adjusted for CSF
contamination (contamination was on average ~1%). GABA concentrations were additionally cor-
rected for the differences in water relaxation times of the different tissue types within the voxel.
Finally, both GABA and Glx concentrations were expressed as a ratio score. Water (H2O) concentra-
tion (unsuppressed) was used as reference.
Statistical Analysis of MR Spectroscopy Data
The computed GABA/H2O, Glx/H2O concentrations, and RATIO scores (Glx/GABA) for each CHR
and CON1 participant were submitted to a one-way repeated-measures ANOVA to determine
group differences in metabolite concentration and/or E/I balance, using 1000 sample bootstrapping,
a confidence interval of 95%, and Welch t-tests as a more robust test of equality of means for our
unequal sample sized data. Results were corrected for multiple comparisons using Least Square Dif-
ference (LSD).
Statistical Analysis MEG, Demographical and Clinical Data
Group differences in whole brain gamma-band power were evaluated by a non-parametric Monte-
Carlo permutation statistics (using 2000 permutations) in combination with independent t-tests and
additional False Discovery Rate (FDR) correction for multiple comparisons. Significance was assumed
for p-values<0.05. Finally, demographic and clinical variables were assessed with an independent
sample Kruskal-Wallis tests, alpha-level 0.05 (two-sided), adjusted for ties. BACS data were standard-
ized (z-transformed) to a normative database, correcting for age and gender (Keefe et al., 2008).
Main GROUP effects for BACS data were followed up by pairwise comparisons, corrected for multi-
ple comparisons using Least Square Differences (LSD).
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